vs
Apellis Pharmaceuticals, Inc.（APLS）与骏利亨德森（JBI）财务数据对比。点击上方公司名可切换其他公司
骏利亨德森的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$219.3M vs $199.9M），骏利亨德森净利率更高（6.9% vs -29.5%，领先36.4%），骏利亨德森同比增速更快（-4.7% vs -5.9%），骏利亨德森自由现金流更多（$8.3M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -8.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
骏利亨德森是一家英美合资的全球资产管理集团，总部位于英国伦敦市。旗下以骏利亨德森投资者为品牌，面向全球个人投资者、中介顾问及机构投资者提供丰富多样的金融产品。
APLS vs JBI — 直观对比
营收规模更大
JBI
是对方的1.1倍
$199.9M
营收增速更快
JBI
高出1.2%
-5.9%
净利率更高
JBI
高出36.4%
-29.5%
自由现金流更多
JBI
多$22.6M
$-14.3M
两年增速更快
APLS
近两年复合增速
-8.8%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $219.3M |
| 净利润 | $-59.0M | $15.2M |
| 毛利率 | — | 39.1% |
| 营业利润率 | -25.6% | 13.4% |
| 净利率 | -29.5% | 6.9% |
| 营收同比 | -5.9% | -4.7% |
| 净利润同比 | -62.2% | 28.8% |
| 每股收益（稀释后） | $-0.40 | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSJBI
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $219.3M | ||
| Q2 25 | $178.5M | $228.1M | ||
| Q1 25 | $166.8M | $210.5M | ||
| Q4 24 | $212.5M | $230.8M | ||
| Q3 24 | $196.8M | $230.1M | ||
| Q2 24 | $199.7M | $248.4M | ||
| Q1 24 | $172.3M | $254.5M |
净利润APLSJBI
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $15.2M | ||
| Q2 25 | $-42.2M | $20.7M | ||
| Q1 25 | $-92.2M | $10.8M | ||
| Q4 24 | $-36.4M | $300.0K | ||
| Q3 24 | $-57.4M | $11.8M | ||
| Q2 24 | $-37.7M | $27.6M | ||
| Q1 24 | $-66.4M | $30.7M |
毛利率APLSJBI
| Q4 25 | — | — | ||
| Q3 25 | — | 39.1% | ||
| Q2 25 | — | 40.9% | ||
| Q1 25 | — | 38.9% | ||
| Q4 24 | — | 37.8% | ||
| Q3 24 | — | 39.6% | ||
| Q2 24 | — | 43.9% | ||
| Q1 24 | — | 43.4% |
营业利润率APLSJBI
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 13.4% | ||
| Q2 25 | -18.6% | 15.8% | ||
| Q1 25 | -50.0% | 12.0% | ||
| Q4 24 | -12.3% | 5.5% | ||
| Q3 24 | -24.0% | 11.6% | ||
| Q2 24 | -14.7% | 20.8% | ||
| Q1 24 | -36.0% | 21.8% |
净利率APLSJBI
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 6.9% | ||
| Q2 25 | -23.6% | 9.1% | ||
| Q1 25 | -55.3% | 5.1% | ||
| Q4 24 | -17.1% | 0.1% | ||
| Q3 24 | -29.2% | 5.1% | ||
| Q2 24 | -18.9% | 11.1% | ||
| Q1 24 | -38.5% | 12.1% |
每股收益（稀释后）APLSJBI
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $0.11 | ||
| Q2 25 | $-0.33 | $0.15 | ||
| Q1 25 | $-0.74 | $0.08 | ||
| Q4 24 | $-0.30 | $0.01 | ||
| Q3 24 | $-0.46 | $0.08 | ||
| Q2 24 | $-0.30 | $0.19 | ||
| Q1 24 | $-0.54 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $560.8M |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSJBI
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | $102.1M | ||
| Q2 24 | $360.1M | $110.1M | ||
| Q1 24 | $325.9M | — |
总债务APLSJBI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSJBI
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $560.8M | ||
| Q2 25 | $156.3M | $543.8M | ||
| Q1 25 | $164.2M | $526.8M | ||
| Q4 24 | $228.5M | $518.8M | ||
| Q3 24 | $237.1M | $526.6M | ||
| Q2 24 | $264.3M | $556.3M | ||
| Q1 24 | $266.7M | $535.4M |
总资产APLSJBI
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $821.4M | $1.3B | ||
| Q1 25 | $807.3M | $1.3B | ||
| Q4 24 | $885.1M | $1.3B | ||
| Q3 24 | $901.9M | $1.3B | ||
| Q2 24 | $904.5M | $1.3B | ||
| Q1 24 | $831.9M | $1.4B |
负债/权益比APLSJBI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $8.3M |
| 自由现金流率自由现金流/营收 | -7.1% | 3.8% |
| 资本支出强度资本支出/营收 | 0.1% | 3.1% |
| 现金转化率经营现金流/净利润 | — | 0.99× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $140.1M |
8季度趋势，按日历期对齐
经营现金流APLSJBI
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $15.0M | ||
| Q2 25 | $4.4M | $51.4M | ||
| Q1 25 | $-53.4M | $48.3M | ||
| Q4 24 | $19.4M | $51.4M | ||
| Q3 24 | $34.1M | $43.0M | ||
| Q2 24 | $-8.3M | $31.0M | ||
| Q1 24 | $-133.0M | $28.6M |
自由现金流APLSJBI
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $8.3M | ||
| Q2 25 | $4.4M | $44.6M | ||
| Q1 25 | $-53.4M | $41.9M | ||
| Q4 24 | $19.3M | $45.3M | ||
| Q3 24 | — | $39.3M | ||
| Q2 24 | $-8.4M | $25.3M | ||
| Q1 24 | $-133.3M | $24.0M |
自由现金流率APLSJBI
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 3.8% | ||
| Q2 25 | 2.5% | 19.6% | ||
| Q1 25 | -32.0% | 19.9% | ||
| Q4 24 | 9.1% | 19.6% | ||
| Q3 24 | — | 17.1% | ||
| Q2 24 | -4.2% | 10.2% | ||
| Q1 24 | -77.3% | 9.4% |
资本支出强度APLSJBI
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 3.1% | ||
| Q2 25 | 0.0% | 3.0% | ||
| Q1 25 | 0.0% | 3.0% | ||
| Q4 24 | 0.0% | 2.6% | ||
| Q3 24 | 0.0% | 1.6% | ||
| Q2 24 | 0.0% | 2.3% | ||
| Q1 24 | 0.2% | 1.8% |
现金转化率APLSJBI
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 0.99× | ||
| Q2 25 | — | 2.48× | ||
| Q1 25 | — | 4.47× | ||
| Q4 24 | — | 171.33× | ||
| Q3 24 | — | 3.64× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | — | 0.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
JBI
| Self Storage New Construction | $72.3M | 33% |
| Commercial And Others | $65.5M | 30% |
| Self Storage R3 | $54.0M | 25% |
| Transferred At Point In Time | $15.5M | 7% |
| Transferred Over Time | $12.8M | 6% |
